• Je něco špatně v tomto záznamu ?

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

ER. Plimack, T. Powles, V. Stus, R. Gafanov, D. Nosov, T. Waddell, B. Alekseev, F. Pouliot, B. Melichar, D. Soulières, D. Borchiellini, RS. McDermott, I. Vynnychenko, YH. Chang, S. Tamada, MB. Atkins, C. Li, R. Perini, LR. Molife, J. Bedke, BI. Rini

. 2023 ; 84 (5) : 449-454. [pub] 20230725

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000899

Previous analyses of KEYNOTE-426, an open-label, phase 3 randomized study, showed superior efficacy of first-line pembrolizumab plus axitinib to sunitinib in advanced clear cell renal cell carcinoma (ccRCC). We report results of the final protocol-prespecified analysis of KEYNOTE-426. Patients received pembrolizumab 200 mg intravenously every 3 wk plus axitinib 5 mg orally twice daily or sunitinib 50 mg orally once daily (4 wk per 6-wk cycle). The dual primary endpoints were overall survival (OS) and progression-free survival (PFS) as per RECIST v1.1 by a blinded independent central review. The secondary endpoints included objective response rate (ORR) and duration of response (DOR). The median study follow-up was 43 (range, 36-51) mo. Benefit with pembrolizumab plus axitinib versus sunitinib was maintained for OS (hazard ratio [HR], 0.73 [95% confidence interval {CI}, 0.60-0.88]), PFS (HR, 0.68 [95% CI, 0.58-0.80]), and ORR (60% vs 40%). The median DOR was 24 (range, 1.4+ to 43+) versus 15 (range, 2.3-43+) mo in the pembrolizumab plus axitinib versus the sunitinib arm. No new safety signals emerged. These results support pembrolizumab plus axitinib as a standard of care for patients with previously untreated advanced ccRCC. PATIENT SUMMARY: Extended results of KEYNOTE-426 support pembrolizumab plus axitinib as the standard of care for advanced clear cell renal cell carcinoma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000899
003      
CZ-PrNML
005      
20240213093445.0
007      
ta
008      
240109s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eururo.2023.06.006 $2 doi
035    __
$a (PubMed)37500340
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Plimack, Elizabeth R $u Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Elizabeth.Plimack@fccc.edu
245    10
$a Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study / $c ER. Plimack, T. Powles, V. Stus, R. Gafanov, D. Nosov, T. Waddell, B. Alekseev, F. Pouliot, B. Melichar, D. Soulières, D. Borchiellini, RS. McDermott, I. Vynnychenko, YH. Chang, S. Tamada, MB. Atkins, C. Li, R. Perini, LR. Molife, J. Bedke, BI. Rini
520    9_
$a Previous analyses of KEYNOTE-426, an open-label, phase 3 randomized study, showed superior efficacy of first-line pembrolizumab plus axitinib to sunitinib in advanced clear cell renal cell carcinoma (ccRCC). We report results of the final protocol-prespecified analysis of KEYNOTE-426. Patients received pembrolizumab 200 mg intravenously every 3 wk plus axitinib 5 mg orally twice daily or sunitinib 50 mg orally once daily (4 wk per 6-wk cycle). The dual primary endpoints were overall survival (OS) and progression-free survival (PFS) as per RECIST v1.1 by a blinded independent central review. The secondary endpoints included objective response rate (ORR) and duration of response (DOR). The median study follow-up was 43 (range, 36-51) mo. Benefit with pembrolizumab plus axitinib versus sunitinib was maintained for OS (hazard ratio [HR], 0.73 [95% confidence interval {CI}, 0.60-0.88]), PFS (HR, 0.68 [95% CI, 0.58-0.80]), and ORR (60% vs 40%). The median DOR was 24 (range, 1.4+ to 43+) versus 15 (range, 2.3-43+) mo in the pembrolizumab plus axitinib versus the sunitinib arm. No new safety signals emerged. These results support pembrolizumab plus axitinib as a standard of care for patients with previously untreated advanced ccRCC. PATIENT SUMMARY: Extended results of KEYNOTE-426 support pembrolizumab plus axitinib as the standard of care for advanced clear cell renal cell carcinoma.
650    _2
$a lidé $7 D006801
650    12
$a karcinom z renálních buněk $x patologie $7 D002292
650    _2
$a axitinib $x škodlivé účinky $7 D000077784
650    _2
$a sunitinib $x terapeutické užití $7 D000077210
650    _2
$a následné studie $7 D005500
650    12
$a nádory ledvin $x patologie $7 D007680
650    _2
$a protokoly protinádorové kombinované chemoterapie $7 D000971
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Powles, Thomas $u Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, London, UK; Queen Mary University of London, London, UK
700    1_
$a Stus, Viktor $u Dnipro State Medical University, Dnipro, Dnipropetrovsk Oblast, Ukraine
700    1_
$a Gafanov, Rustem $u Russian Scientific Center of Roentgenology and Radiology, Moscow, Russia
700    1_
$a Nosov, Dmitry $u Central Clinical Hospital With Outpatient Clinic, Moscow, Russia
700    1_
$a Waddell, Tom $u The Christie NHS Foundation Trust, Manchester, UK
700    1_
$a Alekseev, Boris $u P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Pouliot, Frédéric $u CHU of Québec and Laval University, Québec, QC, Canada
700    1_
$a Melichar, Bohuslav $u Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Soulières, Denis $u Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
700    1_
$a Borchiellini, Delphine $u Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France
700    1_
$a McDermott, Raymond S $u Adelaide and Meath Hospital, University College Dublin, Belfield, Dublin, Ireland
700    1_
$a Vynnychenko, Ihor $u Sumy Regional Oncology Center, Sumy State University, Sumy, Sumy Oblast, Ukraine
700    1_
$a Chang, Yen-Hwa $u Taipei Veterans General Hospital, Taipei, Taiwan
700    1_
$a Tamada, Satoshi $u Bell Land General Hospital, Osaka, Japan
700    1_
$a Atkins, Michael B $u Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA
700    1_
$a Li, Chenxiang $u Merck & Co., Inc., Rahway, NJ, USA
700    1_
$a Perini, Rodolfo $u Merck & Co., Inc., Rahway, NJ, USA
700    1_
$a Molife, L Rhoda $u MSD UK, London, UK
700    1_
$a Bedke, Jens $u University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany
700    1_
$a Rini, Brian I $u Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
773    0_
$w MED00001669 $t European urology $x 1873-7560 $g Roč. 84, č. 5 (2023), s. 449-454
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37500340 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093442 $b ABA008
999    __
$a ok $b bmc $g 2049488 $s 1210593
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 84 $c 5 $d 449-454 $e 20230725 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace